{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:47:45Z","timestamp":1778888865830,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12350-019-01831-8","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T12:19:39Z","timestamp":1566994779000},"page":"371-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis"],"prefix":"10.1016","volume":"27","author":[{"given":"Kathleen R.","family":"Flaherty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Pozniakoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Castano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabahat","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-019-01831-8_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1007\/s12350-019-01831-8_bib2","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-019-01831-8_bib3","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehv328","article-title":"Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction","volume":"38","author":"Castano","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-019-01831-8_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","article-title":"Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis","volume":"9","author":"Longhi","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-019-01831-8_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11897-014-0223-7","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"11","author":"Dhingra","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"10.1007\/s12350-019-01831-8_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1007\/s12350-019-01831-8_bib7","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.2174\/138161208786404155","article-title":"Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses","volume":"14","author":"Sekijima","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s12350-019-01831-8_bib8","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1007\/s12350-019-01831-8_bib9","doi-asserted-by":"crossref","first-page":"S0735","DOI":"10.1016\/S0735-1097(15)60971-8","article-title":"A phase 2, multi-center, open-label trial to evaluate the safety, pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC, AN RNAI therapeutic for the treatment of patients with transthyretin cardiac amyloidosis","volume":"65","author":"Gillmore","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-019-01831-8_bib10","doi-asserted-by":"crossref","first-page":"O21","DOI":"10.1186\/1750-1172-10-S1-O21","article-title":"Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis","volume":"10","author":"Gillmore","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s12350-019-01831-8_bib11","unstructured":"Dorbala S, Bokhari S, Miller E, et al. ASNC PRACTICE POINTS: 99 m Technetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. ASNC Guidelines 2016. http:\/\/www.asnc.org\/Files\/Practice%20Resources\/Practice%20Points\/ASNC%20Practice%20Point-99mTechnetiumPyrophosphateImaging2016.pdf."},{"key":"10.1007\/s12350-019-01831-8_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-019-01831-8_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","article-title":"Amyloidosis","volume":"57","author":"Pepys","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1007\/s12350-019-01831-8_bib14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.amjmed.2015.05.039","article-title":"Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology","volume":"128","author":"Maurer","year":"2015","journal-title":"Am J Med"},{"key":"10.1007\/s12350-019-01831-8_bib15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99 m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1007\/s12350-019-01831-8_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-019-01831-8_bib17","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Non-biopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1007\/s12350-019-01831-8_bib18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-019-01831-8_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1007\/s12350-019-01831-8_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0735-1097(02)01944-7","article-title":"Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography","volume":"40","author":"King","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-019-01831-8_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","article-title":"Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis","volume":"25","author":"Bokhari","year":"2018","journal-title":"J Nucl Cardiol."},{"key":"10.1007\/s12350-019-01831-8_bib22","article-title":"Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction","volume":"122","author":"Mirzoyev","year":"2018","journal-title":"Circulation"},{"key":"10.1007\/s12350-019-01831-8_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002558","article-title":"Transthyretin cardiac amyloidosis in Black Americans","volume":"9","author":"Shah","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1007\/s12350-019-01831-8_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1007\/s12350-019-01831-8_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.12688\/f1000research.7088.1","article-title":"Improved cardiovascular disease outcomes in older adults","volume":"5","author":"Forman","year":"2016","journal-title":"F1000Research"},{"key":"10.1007\/s12350-019-01831-8_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1007\/s12350-019-01831-8_bib27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1007\/s12350-019-01831-8_bib28","first-page":"1769","article-title":"V122I transthyretin variant in elderly black Americans","volume":"372","author":"Gillmore","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-019-01831-8_bib29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","article-title":"Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy","volume":"38","author":"Rapezzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1007\/s12350-019-01831-8_bib30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-019-01831-8_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","article-title":"Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis","volume":"22","author":"Galat","year":"2015","journal-title":"Amyloid"},{"key":"10.1007\/s12350-019-01831-8_bib32","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-019-01831-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12350-019-01831-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123018329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123018329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-019-01831-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:05:11Z","timestamp":1761026711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123018329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1071358123018329"],"URL":"https:\/\/doi.org\/10.1007\/s12350-019-01831-8","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-019-01831-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}